Open AccessLong-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol
Author(s) -
Víctor Arévalos,
Luis OrtegaPaz,
Diego Fernández-Rodríguez,
Víctor Alfonso Jiménez-Díaz,
Jordi Bañeras,
Gianluca Campo,
Miguel Rodríguez-Santamarta,
Armando Pérez de Prado,
Antonio Gómez-Menchero,
José Francisco Díaz Fernández,
Claudia Scardino,
Nieves Gonzalo,
Alberto Pernigotti,
Fernándo Alfonso,
Ignacio J. AmatSantos,
Antonio Silvestro,
Alfonso Ielasi,
José María de la Torre,
Gabriela Bastidas,
Josep Gómez-Lara,
Manel Sabaté,
Salvatore Brugaletta
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0255263
Subject(s) - medicine , myocardial infarction , pulmonary embolism , observational study , disease , retrospective cohort study , heart failure , atrial fibrillation , stroke (engine) , covid-19 , intensive care medicine , emergency medicine , pediatrics , infectious disease (medical specialty) , mechanical engineering , engineering
Background Patients presenting with the coronavirus-2019 disease (COVID-19) may have a high risk of cardiovascular adverse events, including death from cardiovascular causes. The long-term cardiovascular outcomes of these patients are entirely unknown. We aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and to determine their long-term cardiovascular outcomes. Study and design This is a multicenter, observational, retrospective registry to be conducted at 17 centers in Spain and Italy (ClinicalTrials.gov number: NCT04359927). Consecutive patients older than 18 years, who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV2 in the participating institutions, will be included since March 2020, to August 2020. Patients will be classified into two groups, according to the results of the RT-PCR: COVID-19 positive or negative. The primary outcome will be cardiovascular mortality at 1 year. The secondary outcomes will be acute myocardial infarction, stroke, heart failure hospitalization, pulmonary embolism, and serious cardiac arrhythmias, at 1 year. Outcomes will be compared between the two groups. Events will be adjudicated by an independent clinical event committee. Conclusion The results of this registry will contribute to a better understanding of the long-term cardiovascular implications of the COVID19.